A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma

NCT05528679 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: 610 100mg
DRUG: 610 300mg
DRUG: placebo

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.